Replenishing glutathione counters ciprofloxacin-induced acute liver failure via possible gene modifying mechanism

نویسندگان

چکیده

Background: Acute liver failure (ALF) can be defined as rapid loss of functions even in the absence pre-existing disorders. ALF is a medical emergency that necessitates hospitalization and, if not properly treated, transplant may only cure. Herein, we studied potential therapeutic effects exogenous glutathione on drug-induced ALF. Materials: Thirty male Wistar albino rats were used present study. Rats divided (10/group) into: control group (received intra-peritoneal injection distilled water), ciprofloxacin-treated 800 mg/kg/day ciprofloxacin for 15 consequent days with concomitant and + glutathione-treated 200 glutathione). Measurement serum ALT, AST, GGT LDH enzymes activities performed, hepatic gene expression CYP3A, GPx, GSR Nrf2 mRNA was assessed. Results: Treatment resulted significant increase when compared to group. Ciprofloxacin also induced down-regulation corresponding values Glutathione administration significantly normalized up-regulated expression. Conclusion: could play roles treatment acute by preventing oxidative stress-induced disruption hepatocyes cell membranes alteration cytochrome P450 antioxidant genes.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cyproheptadine-Induced Acute Liver Failure

We present the case of a 55-year-old white female with no history of liver or gastrointestinal disease, admitted with acute liver failure following a trial of cyproheptadine for appetite stimulation. The patient was managed with supportive care, symptomatic treatment, and discontinuation of cyproheptadine. To our knowledge, this is the first described case of cyproheptadine-induced acute liver ...

متن کامل

The hepatoprotective role of reduced glutathione and its underlying mechanism in oxaliplatin-induced acute liver injury

Currently, the underlying mechanism of oxaliplatin (OXA) induced live injury is unclear. In addition, there is no standard clinical treatment for OXA-induced acute liver injury (ALI). In this study, we established an animal model of OXA-induced ALI, and studied the role of oxidative stress in OXA-induced ALI and the impacts of reduced glutathione (GSH) treatment on OXA-induced ALI. To establish...

متن کامل

Gene therapy for acute liver failure.

Acute liver failure (ALF) is a life-threatening medical emergency and occurs when the liver rapidly loses its function within a short period. ALF can develop secondary to a variety of causes. Currently, the orthotopic liver transplantation is the "Gold Standard" therapy for the disease. However, due to the limited availability of donor organs and rapid progression of the disease, the mortality ...

متن کامل

Miliary Tuberculosis Induced Acute Liver Failure

Hepatobiliary tuberculosis is uncommon even in endemic countries. It is associated with a high mortality and is even diagnosed early in the disease course. Acute liver failure (ALF) caused by tuberculosis bacilli has been reported in only a few reports. All previous cases have been diagnosed by postmortem examination. Time to antituberculosis treatment is very critical. In case of suggestive fi...

متن کامل

Orthotopic Liver Transplantation for Etanercept-Induced Acute Hepatic Failure; a case report

The occurrence of hepatotoxicity following etanercept (tumor necrosis factor-alpha antagonist) prescription, has been studied well. However, an acute hepatic failure leading to liver transplant as an adverse effect of this drug has not been reported in the literature. In this article, we are going to present a case of acute liver failure followed by liver transplantation, in a 32 years old man ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Bulletin of Egyptian Society for Physiological Sciences

سال: 2021

ISSN: ['1110-0842', '2356-9514']

DOI: https://doi.org/10.21608/besps.2021.63175.1094